Latest Healthcare News

Pro Medicus’ US arm Visage Imaging has landed a significant 7-year, A$90 million contract to deploy its cloud-based Visage 7 platform across Beth Israel Lahey Health, marking another major foothold in North America's healthcare imaging market.

EBR Systems has landed a significant purchasing agreement with Advocate Health, the third-largest US non-profit health system, opening access for its WiSE wireless cardiac pacing technology across 69 hospitals in eight states.

Emyria has launched its first Empax clinic in Victoria on schedule, establishing a new clinical hub with trained staff and dual reimbursement pathways to support growth.

Alcidion Group has acquired Telstra Health's Kyra flow products for $3 million upfront, adding 33 long-term customers and boosting recurring revenue in key Australian states.

Algorae Pharmaceuticals has scaled its AI-driven drug synergy platform from one to 18 anchor drugs, generating over 9 million predictions and identifying thousands of promising combinations for cancer and other diseases.

Atomo Diagnostics has closed a modest Share Purchase Plan, raising $44,500 and issuing free attaching options, while reserving a substantial shortfall for future placement.

Saluda Medical’s Australian arm has secured ASIC approval to bypass standalone audited financial reports, cutting costs and streamlining compliance.

OncoSil Medical’s interim OSPREY Registry data show strong safety and promising survival outcomes for its targeted radiotherapy device in unresectable locally advanced pancreatic cancer, surpassing historical benchmarks.

AVITA Medical reported a 4% revenue increase in Q1 2026 with a narrowed net loss, underpinned by a new BARDA contract and promising Cohealyx clinical data. Leadership changes and regulatory approvals support a confident outlook.

Pacific Edge edges closer to a Medicare breakthrough with a draft Local Coverage Determination proposing coverage for its Cxbladder Triage and Triage Plus tests, potentially unlocking reimbursement for over 66 million US patients.

Lumos Diagnostics has reached a key enrolment milestone in its BARDA-backed FebriDx paediatric trial, unlocking a US$670,000 payment and advancing its FDA submission pathway to expand use in children aged 2-12 years.

Despite sweeping changes to Capital Gains Tax announced in the 2026/27 Federal Budget, Acrux Limited’s status as a Pooled Development Fund ensures its shareholders remain shielded from these new tax rules.